Understand the source comparison
Best Peptides for Menopause Weight Gain: Mechanism and Protocol Comparison
The table below compares mechanisms, clinical evidence, dosing protocols, and administration for the peptides most studied in menopause-related metabolic dysfunction. CJC-1295 + Ipamorelin GHRH analog + ghrelin mimetic; stimulates pulsatile GH release from ant
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares mechanisms, clinical evidence, dosing protocols, and administration for the peptides most studied in menopause-related metabolic dysfunction.
- CJC-1295 + Ipamorelin
- GHRH analog + ghrelin mimetic; stimulates pulsatile GH release from anterior pituitary
- Increases lean mass 1.5–2 kg over 12 weeks; improves sleep quality and recovery markers
- 200–300 mcg each, 5 days/week, bedtime dosing
- Subcutaneous injection
- Best for restoring anabolic signaling; requires consistent dosing for 8+ weeks before fat loss accelerates
- AOD-9604
- C-terminal GH fragment; beta-3 adrenergic activation in adipocytes without GH receptor binding
- 2.8 kg greater fat loss vs placebo (12 weeks); preferential visceral fat reduction
- 300–600 mcg daily, morning fasted state
- Most selective for lipolysis; no appetite suppression; works best in caloric deficit
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic; 24-hour GHSR-1a activation
- +1.1 kg lean mass, −0.4 kg visceral fat over 12 months in elderly cohort
- 12.5–25 mg daily, bedtime
- Oral capsule
- Convenient oral dosing; appetite stimulation is a significant side effect in 40–60% of users
- Tesofensine
- Triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine)
- 10.6% body weight reduction at 24 weeks (phase II trial); increases resting energy expenditure 10–15%
- 0.25–0.5 mg daily
- Strongest appetite suppression and thermogenic effect; not FDA-approved; off-label use only